Evidence map›Paper›PMID 33668370›Full record

ArticleMetabolites2021

Targeted Plasma Metabolic Profiles and Risk of Recurrence in Stage II and III Colorectal Cancer Patients: Results from an International Cohort Consortium.

Jennifer Ose, Biljana Gigic, Stefanie Brezina, Tengda Lin, Andreas Baierl, Anne J M R Geijsen, Eline van Roekel, Nivonirina Robinot, Audrey Gicquiau, David Achaintre and 16 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Characteristics of Cancer Epidemiology Studies That Employ Metabolomics: A Scoping Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 11 institutions in 6 countries.

Jennifer OseHuntsman Cancer Institute Salt Lake City, Salt Lake City, UT 84112, USA.ORCID 0000-0002-2030-9676
Biljana GigicDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, 1, 69117 Heidelberg, Germany.ORCID 0000-0002-8085-2072
Stefanie BrezinaInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, 23, 1090 Wien, Austria.ORCID 0000-0001-5238-6900
Tengda LinHuntsman Cancer Institute Salt Lake City, Salt Lake City, UT 84112, USA.
Andreas BaierlDepartment of Statistics and Operations Research, University of Vienna, 1, 1010 Wien, Austria.ORCID 0000-0002-5329-9507
Anne J M R GeijsenDivision of Human Nutrition and Health, Wageningen University & Research, 6708 Wageningen, the Netherlands.
Eline van RoekelDepartment of Epidemiology, GROW-School of Oncology and Developmental Biology, Maastricht University, 30, 6229 Maastricht, The Netherlands.ORCID 0000-0002-9402-2029
Nivonirina RobinotBiomarkers Group, International Agency for Research on Cancer, 69372 Lyon, France.ORCID 0000-0002-2532-1455
Audrey GicquiauBiomarkers Group, International Agency for Research on Cancer, 69372 Lyon, France.
David AchaintreBiomarkers Group, International Agency for Research on Cancer, 69372 Lyon, France.
Pekka Keski-RahkonenBiomarkers Group, International Agency for Research on Cancer, 69372 Lyon, France.
Fränzel J B van DuijnhovenDivision of Human Nutrition and Health, Wageningen University & Research, 6708 Wageningen, the Netherlands.
Tanja GumpenbergerInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, 23, 1090 Wien, Austria.ORCID 0000-0001-9319-5350
Andreana N HolowatyjHuntsman Cancer Institute Salt Lake City, Salt Lake City, UT 84112, USA.ORCID 0000-0001-8001-8793
Dieuwertje E KokDivision of Human Nutrition and Health, Wageningen University & Research, 6708 Wageningen, the Netherlands.ORCID 0000-0001-7154-8207
Annaleen KooleDepartment of Epidemiology, GROW-School of Oncology and Developmental Biology, Maastricht University, 30, 6229 Maastricht, The Netherlands.ORCID 0000-0002-9927-9034
Petra Schrotz-KingDivision of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), 460, 69120 Heidelberg, Germany.
Alexis B UlrichDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, 1, 69117 Heidelberg, Germany.
Martin SchneiderDepartment of General, Visceral and Transplantation Surgery, University of Heidelberg, 1, 69117 Heidelberg, Germany.
Arve UlvikBEVITAL, 87, 5021 Bergen, Norway.
Per-Magne UelandBEVITAL, 87, 5021 Bergen, Norway.
Matty P WeijenbergDepartment of Epidemiology, GROW-School of Oncology and Developmental Biology, Maastricht University, 30, 6229 Maastricht, The Netherlands.
Nina HabermannGenome Biology, European Molecular Biology Laboratory (EMBL), 69117 Heidelberg, Germany.
Augustin ScalbertBiomarkers Group, International Agency for Research on Cancer, 69372 Lyon, France.ORCID 0000-0001-6651-6710
Andrea GsurInstitute of Cancer Research, Department of Medicine I, Medical University of Vienna, 23, 1090 Wien, Austria.ORCID 0000-0002-9795-1528
Cornelia M UlrichHuntsman Cancer Institute Salt Lake City, Salt Lake City, UT 84112, USA.ORCID 0000-0001-7641-059X
Centre international de recherche sur le cancer · FRHeidelberg University · DEMaastricht University · NLMedical University of Vienna · ATUniversity of Utah · USWageningen University & Research · NLBevital (Norway) · NOEuropean Molecular Biology Laboratory · DEGerman Cancer Research Center · DEUniversity of Vienna · ATVanderbilt University · US

Funding

Penn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Building Interdisciplinary Research Careers in Women's HealthK12HD043483 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARTMANN, KATHERINE E, MAJOR, AMY S · 2002 to 2023
$10.3M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Development, Implementation and AssessMent of Novel Training in Domain-based Competencies (DIAMOND)U01TR002013 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELLINGROD, VICKI L, JONES, CAROLYNN THOMAS · 2017 to 2019
$2.3M
MONOCLONAL ANTIBODY IMAGING IN NUCLEAR MEDICINEK11CA001503 · NCI · YESHIVA UNIVERSITY · PI ZUCKIER, LIONEL S · 1990 to 1994
–
NCI NIH HHS France, project no. 2014-007NCI NIH HHS R01 CA207371NCI NIH HHS U01 CA206110NICHD NIH HHS K12 HD043483World Health Organization 001
6 · The paper itself

Abstract

The identification of patients at high-risk for colorectal cancer (CRC) recurrence remains an unmet clinical need. The aim of this study was to investigate associations of metabolites with risk of recurrence in stage II/III CRC patients. A targeted metabolomics assay (128 metabolites measured) was performed on pre-surgery collected EDTA plasma samples from n = 440 newly diagnosed stage II/III CRC patients. Patients have been recruited from four prospective cohort studies as part of an international consortium: Metabolomic profiles throughout the continuum of CRC (MetaboCCC). Cox proportional hazard models were computed to investigate associations of metabolites with recurrence, adjusted for age, sex, tumor stage, tumor site, body mass index, and cohort; false discovery rate (FDR) was used to account for multiple testing. Sixty-nine patients (15%) had a recurrence after a median follow-up time of 20 months. We identified 13 metabolites that were nominally associated with a reduced risk of recurrence. None of the associations were statistically significant after controlling for multiple testing. Pathway topology analyses did not reveal statistically significant associations between recurrence and alterations in metabolic pathways (e.g., sphingolipid metabolism

Indexed as

colorectal cancerrecurrencetargeted metabolomics

Identifiers

PMID33668370
PMCPMC7996362
OpenAlexW3130573629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.